Location History:
- Los Angeles, CA (US) (2009)
- Quebec, CA (2006 - 2011)
Company Filing History:
Years Active: 2006-2011
Title: The Innovative Mind of Eric Petitclerc
Introduction
Eric Petitclerc, an accomplished inventor based in Quebec, Canada, has made significant strides in the field of angiogenesis research. With a total of four patents to his name, his contributions are paving the way for potential therapeutic advancements in treating various medical conditions.
Latest Patents
Eric's latest patents focus on "Antagonists and methods for inhibiting angiogenesis." These inventions detail methods for inhibiting angiogenesis in tissues by administering an antagonist that specifically binds to proteolyzed or denatured collagen, distinguishing it from native, triple helical forms of collagen. The patented antagonists are capable of targeting several types of denatured collagens, including type-I, type-II, type-III, type-IV, type-V, and their combinations. Furthermore, Eric's work describes how these antagonists can be utilized for therapeutic treatments related to tumor growth, tumor metastasis, and restenosis. It also explores their potential as diagnostic markers for angiogenesis in both normal and diseased tissues, both in vivo and ex vivo. Notable antagonists from his inventions include monoclonal antibodies designated as HUI77, HUIV26, and XL313.
Career Highlights
Eric Petitclerc is associated with the University of Southern California, where he continues to innovate and research. His academic and professional journey is marked by a strong focus on developing therapies aimed at inhibiting harmful angiogenic processes within tissues.
Collaborations
Throughout his career, Eric has collaborated with notable colleagues such as Peter C Brooks and Jingsong Xu. These partnerships highlight a network of talented professionals dedicated to advancing the field of medical science through innovative research and development.
Conclusion
Eric Petitclerc stands as a testament to the impact of dedicated research and innovation in the field of biotechnology. With his patents addressing crucial issues in angiogenesis, his work promises to enhance understanding and treatment options for conditions related to tumor growth and other vascular diseases. As he continues his research at the University of Southern California, the medical community eagerly anticipates his future contributions.